Given that PARP inhibitors have demonstrated efficacy in overcoming chemoresistance in prostate, pancreatic, and lung cancers [44, 45], further exploration of their use in combination with transcription factor inhibitors could define a new paradigm in precision oncology. This evidence concerns the gene PARP1 and lung carcinoma.